IntelGenx has created a scientific advisory board with the engagement of Dr. Ludwig Aigner and Dr. Barry Greenberg. Dr. Horst G. Zerbe will act as the chairman and Nadine Paiement (vice president, R&D) will serve as vice-chair of the scientific advisory board.
"We are honored to have two distinguished neuroscientists join IntelGenx' new scientific advisory board," said Zerbe, president and CEO of IntelGenx. "We are enlisting these noted experts to assist with pipeline targeting, including the identification of innovative projects with the focus of maximizing the value of our drug delivery technologies in drug repurposing."
Aigner is a neuroscientist that has made major contributions in the field of brain and spinal cord regeneration over the last 25 years. He received his Ph.D at the University of Basel, Switzerland. Aigner is currently professor and head of the Institute of Molecular Regenerative Medicine at the Paracelsus Medical University in Salzburg, Austria. He is president of the Austrian Neuroscience Association and scientific board member of the Wings For Life spinal cord injury foundation.
Greenberg has been involved in Alzheimer's disease research and drug discovery since 1985. He has held a series of positions internationally in the U.S., Sweden and Canada within the biotechnology and pharmaceutical industries. Greenberg led a drug discovery project at AstraZeneca. Before joining Toronto's United Health Network (UHN) as director, neuroscience drug discovery and development, he was senior director of pharmacology at Neurochem, responsible for the preclinical biology research program and a contributor to the analyses of the phase III Alzhemed trial. At UHN, he is also co-directing the Toronto Dementia Research Alliance (TDRA) as director of strategy, a consortium involving academic research and the five memory clinics at hospitals affiliated with the University of Toronto to create a citywide dementia research center.
In 2012 he was a member of the committee responsible for drafting the scientific strategic recommendations to inform the National Alzheimer Plan in the U.S.